Grierson H L, Wooldridge T N, Purtilo D T, Pierson J, Bast M, Wooldridge L, Armitage J O, Weisenburger D D
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68105.
Cancer Res. 1990 Aug 15;50(16):4845-8.
Peripheral T-cell lymphoma (PTCL) consists of a diverse group of post-thymic tumors bearing a mature T-cell phenotype and, excluding mycosis fungoides, comprises approximately 10-20% of the non-Hodgkin's lymphomas in the United States. This category of non-Hodgkin's lymphomas exhibits considerable morphological, immunological, and clinical diversity and is generally considered to be a high-grade malignancy. In the present study, paraffin-embedded biopsy specimens of lymph nodes from 31 patients with PTCL who were treated with curative intent were evaluated by flow cytometry for DNA ploidy and proliferative activity (PA). DNA ploidy was not predictive of the clinical outcome. However, low PA, defined by less than or equal to 10% of cells in S + G2M phase of cell cycle, was associated with a favorable prognosis. Patients with tumors having low PA had a significantly higher complete remission rate (100%) as compared to those with high PA (55%; P less than 0.02), and the predicted actuarial 4-year survival of those with low PA was 85% versus only 50% for those with high PA (P less than 0.04). This is the first report of the effects of PA and DNA ploidy in patients with PTCL who were treated with curative intent. Additional studies of similar patients are needed to confirm these findings.
外周T细胞淋巴瘤（PTCL）由一群具有成熟T细胞表型的胸腺后肿瘤组成，除蕈样肉芽肿外，约占美国非霍奇金淋巴瘤的10%-20%。这类非霍奇金淋巴瘤在形态学、免疫学和临床上表现出相当大的多样性，通常被认为是一种高级别恶性肿瘤。在本研究中，对31例接受根治性治疗的PTCL患者的淋巴结石蜡包埋活检标本进行了流式细胞术检测，以评估DNA倍体和增殖活性（PA）。DNA倍体不能预测临床结果。然而，PA低（定义为处于细胞周期S+G2M期的细胞小于或等于10%）与良好的预后相关。PA低的肿瘤患者的完全缓解率（100%）显著高于PA高的患者（55%；P<0.02），PA低的患者预计4年精算生存率为85%，而PA高的患者仅为50%（P<0.04）。这是关于PA和DNA倍体对接受根治性治疗的PTCL患者影响的首次报告。需要对类似患者进行更多研究以证实这些发现。
